Improving the biopharmaceutical attributes of mangiferin using vitamin E-TPGS co-loaded self-assembled phospholipidic nano-mixed micellar systems

Rajneet Kaur Khurana1 · Balan Louis Gaspar2 · Gail Welsby3 · O. P. Katere1 · Kamalinder K. Singh3 · Bhupinder Singh1,4

Published online: 10 April 2018 © The Author(s) 2018

Abstract

The current research work encompasses the development, characterization, and evaluation of self-assembled phospholipidic nano-mixed miceller system (SPNMS) of a poorly soluble BCS Class IV xanthone bioactive, mangiferin (Mgf) functionalized with co-delivery of vitamin E TPGS. Systematic optimization using I-optimal design yielded self-assembled phospholipidic nano-micelles with a particle size of < 60 nm and > 80% of drug release in 15 min. The cytotoxicity and cellular uptake studies performed using MCF-7 and MDA-MB-231 cell lines demonstrated greater kill and faster cellular uptake. The ex vivo intestinal permeability revealed higher lymphatic uptake, while in situ perfusion and in vivo pharmacokinetic studies indicated nearly 6.6- and 3.0-folds augmentation in permeability and bioavailability of Mgf. In a nutshell, vitamin E functionalized SPNMS of Mgf improved the biopharmaceutical performance of Mgf in rats for enhanced anticancer potency.

Keywords
Breast cancer · Quality by design (QbD) · Mangiferin · Vitamin E TPGS nanomicelles · Self-assembled phospholipidic nano-mixed miceller system (SPNMS) · Pharmacokinetics · Bioavailability · P-gp efflux · Cellular uptake

Introduction

Mangiferin (Mgf), a naturally produced polyphenol molecule possessing four hydroxyl groups, is an efficient antioxidant for free radical chain termination [1]. Mgf shows potential cytotoxicity effects on cancer cells and may even induce apoptosis by inhibiting and suppressing nuclear factor kappa B (NF-kB) and NF-κB-inducing kinase [2, 3]. Several literature [3, 4] also report Mgf-induced apoptosis, and tumorigenesis through altered gene expression [5–7], especially using Bcl-2 and Bax. Definitive activity of this bioactive phytochemical has also been documented on HL-60 cells programmed cell death, ascribed to suppression of Bcl-xL and XIAP expression and inhibition of the NF-kB pathway [8].

Despite being a very potent antioxidant molecule, Mgf exhibits very low and variable bioavailability (i.e., 1.5 to 5%), owing principally to limited aqueous oral solubility (i.e., 0.1 to 0.3 mg/mL) and poor lipophilicity (i.e., log P of −0.56), extensive P-gp efflux, high first-pass effect, and considerable metabolism by gut Cytochrome P-450 enzymes [9–14]. By virtue of its low aqueous solubility and lipophilicity, Mgf can be safely regarded as a BCS class IV agent.

Owing to the aforementioned challenges [15], several scientists have attempted to enhance the oral bioavailability of Mgf by formulating its solid dispersions [16], β-cyclodextrin complexes [17, 18], phospholipid complexes [19], and spray-
dried encapsulation [5]. None of the conventional formulations, therefore, is considered to be highly satisfactory in completely surmounting the multifactorial issues of solubility, lipophilicity, and eventually the bioavailability of Mgf. However, the increase of Mgf bioavailability compared to the plain drug has previously been observed with nanostructured lipidic carriers (NLCs) carrying Mgf and Mgf-phospholipid complex [20], indicating safety towards Caco-2 cells with enhanced intestinal permeation parameters. The amphiphilic nature of phospholipids is documented to enhance solubility and permeability of the drugs, thus improving their oral biopharmaceutical performance [22]. Other stellar merits of phospholipidic formulations include ease of preparation, along with high drug loading capacity and long-term stability. Further, the employed emulgents and co-emulgents lead to complete micellization of the system and thus solubilizing the BCS class IV bioactive, leading eventually to improved absorption potential and thus better bioavailability.

The phospholipid systems have lately been explored for enhancing the biopharmaceutical performance and therapeutic efficacy of several bioactives exhibiting poor hydrophilicity and lipophilicity [20]. As phospholipids constitute major part of the bio-membrane, these hold good biocompatibility, while acting as a carrier for delivering drugs across the biological barriers. Attempts were, therefore, made in the current studies for improving the drug loading potential, enhancing dissolution rate, and augmenting the oral bioavailability of Mgf employing systematically prepared functional SPNMS with co-delivery of TPGS, and evaluating these extensively for their biopharmaceutical attributes. Further, its anticancer potential and cellular uptake in mammary adenocarcinoma cell lines (MDA-MB-231 and MCF-7) have also been investigated. Also, toxicity of the developed and blank formulations was evaluated by excising out all the vital organs followed by their histopathological examination. The present research article offers an insight to use the functionalized SPNMS for improving the biopharmaceutical attributes of Mgf. In vitro, in situ, and in vivo studies carried out on the formulations proved these nanostructures to be highly superior to the pure bioactive.

**Materials and methods**

Mgf was obtained from M/s International Association on Mangiferin Research (IAMR), Nanning, Guangxi, China. Vitamin E TPGS and poly(ethylene glycol) 200 (PEG 200) were purchased from M/s Sigma-Aldrich, Chemicals Pvt. Ltd., Mumbai, India. Phospholipid 90G was provided as gift samples by M/s ACG Associated Capsules Pvt. Ltd., Mumbai. Empty gelatin capsule shells (size 00) were purchased from M/s Associated Capsules Pvt. Ltd., Mumbai.

**Identifying quality target product profile and critical quality attributes**

As the first and foremost step, quality target product profile (QTPP) was embarked upon as the formulation objectives (Supplementary Table 1) to achieve the maximal therapeutic efficacy for enhancing the bioavailability of Mgf. Valid justification(s) were documented for choosing the apt critical quality attributes (CQAs) to subsequently formulate SPNMS of Mgf (Supplementary Table 2), using the systematic approach of Quality by Design (QbD).
Risk assessment studies

Risk assessment studies were performed to identify, analyze, and assess the possible interaction(s) among Mgf, excipients, and other process parameters. Ishikawa fishbone cause-and-affect diagram was constructed and failure mode effect analysis (FMEA) was carried out in order to earmark the critical material attributes (CMAs) and/or critical process parameters (CPPs) for SPNMS of Mgf [36].

Equilibrium solubility studies

Solubility studies for Mgf were carried out for 72 h at 37 ± 1 °C in a water bath by adding an excess amount of drug in various water-soluble emulgents, viz. Acconon CC-6, Cremophor RH40, Cremophor EL, Vitamin E TPGS, Labrafil M1944, Labrasol, Tween 80 and Tween 40. Cosolvents employed included Transcutol HP, PEG 200, and propylene glycol. Aliquots of the filtrate were suitably diluted with methanol and analyzed using the HPTLC method previously reported by the authors at a $\lambda_{max}$ of 262 nm [37].

Construction of pseudo-ternary phase diagrams

Phase titration studies were conducted on Phospholipid 90G, Vitamin E TPGS (emulgents), and PEG 200 (cosolvent) as the surfactant mixture (Smix; in the ratio 1:0.1:1:2:1, and 3:1) in the varying ratios, ranging from 1 to 9, were titrated with water at 37 °C to attain the maximal emulsification region [38]. Pseudo-ternary diagrams were constructed using the PCP Disso software ver 3.0 (M/s Pune College of Pharmacy, Pune, India).

Preparation of Mgf SPNMS

SPNMS of Mgf (dose equivalent to 30 mg) were prepared by employing the self-assembly method [39]. Mgf was complexed with Phospholipid 90G (1:1) as per the already developed method [20]. Subsequently, addition of vitamin E TPGS and PEG 200 in ethanolic mixture was carried out using magnetic stirrer at room temperature. Afterwards, butylated hydroxyl tolenue (BHT) 0.2% w/w of the total lipid was dissolved in the above alcoholic solution. The aqueous phase containing phosphate buffer saline (pH 7.4), sodium metabisulphite (0.5% w/w), and 0.01% of Triton X-100 was poured into the organic phase in a streamlined manner with continuous stirring at 2000 rpm. The dispersion was stirred for 5–10 min after complete addition of the aqueous phase [40, 41].

QbD-based formulation optimization studies

For systematic optimization of Mgf-SPNMS formulations, an I-optimal mixture design matrix was constructed with 16 runs including five replicates, using the Design Expert® software version 9.0.1 (M/s Stat-Ease, Minneapolis, USA) in order to optimize the amounts of CMAs viz. Phospholipid 90G (X1), vitamin E TPGS (X2), and PEG 200 (X3). Various levels of CMAs were deduced from the pseudoternary phase diagrams. Supplementary Table 3 displays the design matrix for all the prepared formulations containing 30 mg of Mgf. All the prepared formulations were evaluated for Q15, %DE, $D_{nn}$, and $T_{emul}$ as the CQAs.

QbD-enabled data analysis and validation

In order to correlate CMAs with CQAs, multiple linear regression analysis (MLRA) was applied to get the coefficients of polynomial equations employing [35]. Various model parameters like $p$ value, coefficient of correlation ($R$), and predicted error sum of squares (PRESS) were analyzed. Besides, 3D-response surface and 2-D contour plots were generated to relate CQAs with CMAs. Further, optimum solution was located by numerical optimization using maximization of the desirability function value, close to unity.

Characterization of SPNMS

Self-emulsification time ($T_{emul}$)

A single dose of the prepared Mgf-SPNMS (1 g) was poured drop-wise in 250 mL of 0.1 N HCl, while stirring at 50 rpm, using a USP XXXI Apparatus II (DS 8000, M/s Lab India Instruments, Mumbai, India) at ambient temperature. The emulsification time was assessed visually and medium was observed for self-emulsification in triplicate.

Globule size ($D_{nn}$) and zeta potential

SPNMS were prepared by dilution (1 mL) in triplicate for $D_{nn}$ and zeta potential analysis employing Zetasizer ZS 90, (M/s Malvern Instruments, Worcestershire, UK [42].

In vitro dissolution studies

The dialysis bag method was employed to study the in vitro release of Mgf from Mgf-SPNMS. Dissolution studies on the SPNMS formulation ($n=6$), incorporated in hard gelatin capsules, were conducted in 250 mL of 0.01 N HCl containing 0.5% SLS using USP 31 Type II Apparatus, stirred at 50 rpm at ambient temperature. An aliquot of 5 mL each of the dissolution medium was withdrawn periodically, and replaced with fresh medium to maintain the sink conditions; analysis of Mgf.
was carried out at a λ\text{max} of 262 nm using the HPTLC technique. From the drug release profile, CQAs like drug release in 15 min (Rel15min), mean dissolution time (MDT), and dissolution efficiency (DE) were calculated.

**Transmission electron microscopy (TEM)**

The formulation was observed for microscopy by placing it on a copper grid, stained with phosphotungstic solution (1%) for 30 s (JEM-2100 F, M/s Jeol, Tokyo, Japan).

**Ex vivo permeation studies**

The method has already been elaborated in one of the published works reported previously by our group [43]. The permeation studies were carried out by excising out the small intestine of sacrificed rats, washed with Kreb’s Ringer Buffer (KRB). The jejunal portion was everted on a glass rod after ligation with a thread and equilibrated subsequently in thermoregulated KRB solution. An accurately weighed amount of pure Mgf and optimized Mgf SPNMS (30 mg Mgf) were placed in bath medium outside the gut sac. From the gut sac, aliquots of samples (of 1 mL each) were periodically withdrawn and analyzed using HPTLC to discern the percentage of drug permeated in 45 min (Perm45min).

**MCF-7 and MDA-MB-231 cell-based testing**

**Cell culture**

Human breast adenocarcinoma cells (MCF-7) were obtained from the University of Manchester, UK, and MDA-MB-231 cell lines were purchased from the European Collection of Authenticated Cell Cultures (ECACC), Public Health England, Salisbury, England. To grow MCF-7 cell lines, Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma) and tissue culture flasks were employed (75 cm²) and maintained constantly in an incubator at 37 °C with 5% CO2. The culture was trypsinized using 1% trypsin, once the cells were 90% confluent. Similarly, to grow MDA-MB-231 cells, L-15 Medium (Leibovitz) was employed at 37 °C without CO2. Medium (Leibovitz) was employed at 37 °C without CO2. The culture was trypsinized using 1% trypsin, once the cells were 90% confluent. Similarly, to grow MDA-MB-231 cells, L-15 Medium (Leibovitz) was employed at 37 °C without CO2.

**Cell viability assay**

The concentration- and time-dependent cell viability assay of Mgf, blank SPNMS, and Mgf SPNMS were assessed on MCF-7 and MDA-MB-231 cell lines using PrestoBlue cell viability reagent (Invitrogen, USA). Briefly, an aliquot of 100 μL of medium containing 1000 cells per well was seeded in 96-well culture plate (Costars, Corning Inc., NY, USA) and incubated for a period of 24 h. The medium was replaced with 90 μL of different concentrations (10–1000 nM) of the said formulations. Cells were treated with the formulations in separate culture plates before incubating for 24, 48, and 72 h at 37 °C on 5% CO2. Before calculating the fluorescence, 10 μL PrestoBlue was added 1 h before and the culture plates were incubated at the end of respective time interval [39, 44]. Cell viability was determined using fluorescence measurement at excitation and emission wavelengths of 560 and 590 nm, respectively, and expressed as percentage normalized to untreated controlled cells.

**Qualitative and quantitative cellular uptake**

Investigations for qualitative cellular uptake were conducted by fluorescence microscopy on MCF-7 and MDA-MB-231 cell lines employing Rhodamine 123 (Rh-123) as a tracker dye, loaded in SPNMS [45]. Cells (1 × 10⁵ per well), both for MCF-7 and MDA-MB-231, were plated onto glass cover slips in DMEM and L-15 media, respectively, and allowed to adhere for overnight. Once adhered, the cells were treated with 0.064 μM Rh-123-loaded SPNMS for 15 min to 4 h separately at 37 °C. Pre-warmed PBS was used to wash cells thrice, subsequently fixed for 20 min at room temperature using 4% (v/v) paraformaldehyde. Cells adhering to microscopic slides were washed thrice with PBS prior to mounting with Vectashield®, a mounting medium containing 300 nM of DAPI (4′,6-diamidino-2-phenylindole), a fluorescent stain for nucleus staining. Cells were imaged on a modified cell observer imaging system (Zeiss EC Plan-Neofluar × 40/1.3 oil objective). Rh-123 and DAPI were imaged using a GFP/DAPI filter set with Ex/Em wavelength of 450–490 nm/500–550 nm and 335–383 nm/420–470 nm, respectively. Analysis of the images was carried out using the Zeiss ZEN desk imaging software. For quantitative measurement, cells (1 × 10⁵) were seeded in each well of six-well plate and incubated for overnight. Rh-123-loaded SPNMS (100 μg/mL) were added to each well of the six-well plate and incubated for different time intervals, in a manner similar to qualitative measurement [44, 46]. After respective time points, medium containing SPNMS was removed and cells were trypsinized and re-suspended in PBS for immediate flowcytometry analysis. Rh-123 signals were detected in FL-1 channel of BD FACSAria flowcytometer. A total of 10,000 events were processed and data were analyzed on Flowing version 2.5.1 (PertuuTerho, Turku Centre for Biotechnology, University of Turku, Finland).

**P-gp efflux assay**

Overexpression of P-gp in MCF-7 and MDA-MB-231 cells is well-documented in literature [47–49]. P-gp efflux pump does not let anticancer drugs to accumulate within the cell by effluxing it time and again, thereby preventing their cytotoxic or apoptotic effects on cancer cells. For evaluating the P-gp efflux, the multi-drug resistance dye efflux
assay kit (Chemicon International, USA) was employed in which the MCF-7 and MDA-MB-231 cells (2.5 x 10^5) were treated with Rh-123 and DiOC_2_2 dyes, with or without vinblastine. To assess the inhibitory activity of SPNMS on MDR1 transporters, these were incubated with Rh-123 alone, Rh-123 with SPNMS, and Rh-123 with vinblastine at 37 °C, along with Rh-123 at 4 °C. Likewise, to estimate the potential of the developed SPNMS formulation for blocking the activity of BCRP transporters, DiOC_2_2 dye was employed. On similar heels, MCF-7 and MDA-MB-231 cells (2.5 x 10^5) were incubated with DiOC_2_2 alone, DiOC_2_2 with SPNMS, and DiOC_2_2 with vinblastine at 37 °C, along with DiOC_2_2 at 4 °C. The fluorescence intensity was measured in a TECAN fluorescence microplate reader at an excitation wavelength of 485 nm and an emission wavelength of 530 nm [50].

**Animal Studies**

**Animals**

Animal studies were carried out on Sprague Dawley (SD) rats in bred and housed in Central Animal House, Panjab University, Chandigarh, India. Standard housing conditions were maintained and animals were kept on regular solid feed and water ad libitum. The animal experiments were performed in accordance with the recommendations of the committee for the purpose of control and supervision of experiments on animals (CPSCEA), India. The study protocol was approved by the institutional animal ethics committee (IAEC) of Panjab University, Chandigarh (Protocol no. 578/IAEC dated 1/08/2016).

**Intestinal permeation study of Mgf: Confocal laser scanning microscopy**

Small intestine from the abdominal cavity of SD rats (n = 3) was excised after sacrificing the rat and flushed it with 0.9% sodium chloride solution to remove any traces of feces and blood. Rh-123-loaded SPNMS formulation was introduced in the intestine and kept for 2 h [51]. Microm HM 525 U Cryostat, Thermo Fisher Scientific, USA, was employed for the study with a microtome, i.e., a slicer and a freezer. The intestine specimen was placed on a metal tissue disc, embedded in OCT, consisting of polyethylene glycol and polyvinyl alcohol, secured in a chuck, and frozen (~20 to ~30 °C) rapidly to slice up to 10-μm sections. The section was placed on a glass slide mounted with glycerol, covered with a cover slip to capture the image with the confocal microscope (CLSM) (NIKON C2 PLUS, software IVIS Elements AR).

**In situ intestinal perfusion**

The in situ perfusion studies were performed as per the procedure previously reported in literature [52]. Briefly, unisex SD rats were put on fasting overnight and divided into two groups with three animals per group, viz. plain Mgf and Mgf-SPNMS. Anesthetized animals were slit open at their abdomen and their jejunum was incised at the upper and lower parts for 4 cm to perfuse KR. An aliquot of perfusate (1 mL each) was withdrawn periodically and the content of Mgf was analyzed using the HPTLC analysis at 262 nm [37]. Various absorption and permeability parameters were calculated as per the details mentioned in Supplementary Section 2A.

**In vivo pharmacokinetic studies**

In vivo pharmacokinetic studies were conducted by sparse sampling designed experiment. The formulations were administered through oral gavage on two groups of rats (n = 60). Within each group, five subgroups were designated (5 x 6 = 30 animals were employed in one group) and from one animal maximum two blood samples were withdrawn during the entire study alternating between left and right eyes. Group I was administered plain Mgf solution and Group II was given Mgf-SPNMS containing Mgf equivalent to 30mg/Kg [39]. The animals were anesthetized employing isoflurane, and the blood (200 μL) was withdrawn from the retro-orbital plexus of rats at 0.5, 1, 2, 3, 6, 12, 18, 24, and 36 h, in heparin-coated micro-centrifuge tubes.

Further, plasma was harvested by centrifugation at 10,000 rpm (559 g) for 5 min and analyzed for Mgf using the previously reported and validated HPTLC method [37]. The data were analyzed by non-compartmental and compartmental pharmacokinetic modeling approaches using the WinNonlin software, version 5.0 (M/s Thermo Scientific, USA) [53]. Statistical tests like one-way/two-way ANOVA followed by post hoc multiple comparison tests, and Student’s independent t test has been applied wherever applicable.

**Histopathology and hematological studies**

A total of 12 SD female rats were divided into four groups, with three animals in each group. Plain Mgf, blank SPNMS, and Mgf-SPNMS (containing an equivalent amount of 30 mg/kg Mgf) were administered three times per week for 4 weeks in total by oral gavage with suitable intubation cannula. Animals of control group were administered normal saline. At the end of the study, the animals were euthanized by isoflurane. All the vital organs were excised, and fixed in 10% formalin for a minimum period of 24 h. Further, the tissues were passed through a cascade of steps like dehydration with
increasing score of ethyl alcohol, clearing in xylol and mounting in molten paraplast at 58–62 °C [54], staining of sections of 5 μm with hematoxylin and eosin stain (H&E), and subsequent observation for any histopathological change(s) vis−à-vis control under a light microscope. The further procedural details of the histopathology are in Supplementary Section 2C.

Further, after anesthetizing the rats, the blood was collected into 10-ml citrate-phosphate-dextrose anticoagulant vacuum tubes (Haematologic Technologies Inc., USA) by cardiac puncture. Harvested blood was centrifuged (2200×g, 10 min at 4 °C), and the plasma and buffy coat were removed by aspiration. The thin smear slide of the blood from each group was observed under light microscopy. The further procedural details of the hematology are in Supplementary Section 2C.

Results and discussion

Risk Assessment Studies

Supplementary Fig. 1 displayed the Ishikawa diagram with the aim to identify CQAs of Mgf-SPNMS, constructed with the help of the Minitab 16 software; FMEA (Supplementary Table 4) was carried out to estimate the risk(s) caused by selected MAs and/or PPs.

Preliminary Screening

The equilibrium solubility studies revealed that among the surfactants, maximum solubilized fraction of Mgf, i.e., 17.64 mg.mL−1, was observed in vitamin E TPGS (Supplementary Fig. 2A). Among the cosolvents, the highest solubility of Mgf was observed in PEG 200 (i.e., 10.23 mg.mL−1) (Supplementary Fig. 2B). For better solubilization of the drug in SPNMS, proper selection of emulgent and cosolvents is quite imperative, and their emulsification properties are based upon the reduction in energy required to emulsify [55]. The cosolvents further help in reduction of interfacial tension and formation of very fine droplets [56]. Further, it was evident from the ternary diagrams that the Smin (3:1) formed a wider nanoemulsion region, as illustrated in Supplementary Fig. 3(A−D).

Factor screening studies

Pareto charts and half-normal plots revealed the effect of MAs/PPs on the studied CQAs (i.e., Rel15min, Dnm, and T_emul) divulging that vitamin E TPGS (emulgent) and PEG 200 (cosolvent) were highly influential, as their effect was beyond t value and Bonferroni line limits (Supplementary Fig. 4(A–F)). Emulgent was found to exert a notable effect on the Rel15min, Dnm, and T_emul, while coemulgent and cosolvent had higher influence on Dnm, and T_emul. Nevertheless, the other employed factors like type of mixing, stirring speed, stirring time, and temperature were kept as constant for further studies, as these caused only a trifling effect on the studied CQAs.

QbD-based model development and response surface analysis

The MLRA technique was employed to build second-order quadratic model and the coefficients for each of the CQAs [57] (Eq. 1). Excellent fit of the data was quite apparent from high values of coefficient of correlation, ranging between 0.965 and 0.998 (p < 0.001 in all the cases).

\[
Y = \beta_1 X_1 + \beta_2 X_2 + \beta_3 X_3 + \beta_4 X_1 X_2 + \beta_5 X_1 X_3 \\
+ \beta_6 X_2 X_3 + \beta_7 X_1 X_2 X_3 + \beta_8 X_1 X_2 (X_1 - X_2) \\
+ \beta_9 X_1 X_3 (X_1 - X_3) + \beta_{10} X_2 X_3 (X_2 - X_3)
\]

where, Y is the response variable, \( \beta_1 \) to \( \beta_4 \) are the coefficients of linear model terms, \( \beta_5 \) to \( \beta_7 \) are the coefficients of quadratic model terms, \( \beta_8 \) to \( \beta_{10} \) are the coefficients of cubic model terms with added interaction terms, while \( X_1 \), \( X_2 \), and \( X_3 \) represent the factors employed (Supplementary Table 5).

The generated response surface plots helped in inclusive understanding of the impact of CMAs on the studied CQAs. The 3D-response surface plot in Fig. 1a indicates combined influence of all the CMAs, i.e., Phospholipid 90G, vitamin E TPGS, and PEG 200 on the studied CQA, i.e., globule size. A trivial increase in Dnm was observed at the high levels of Phospholipid 90G and intermediate levels of vitamin E TPGS, while a decreasing trend was noticed at the high levels of PEG 200. The minimum value for globule size was noticeable at the intermediate to high levels of vitamin E TPGS, and the intermediate levels of PEG 200, respectively. Smaller globule size, as is well-documented, is highly desirable for quicker absorption of drug into the systemic circulation [58].

Figure 1b depicts an umbrella-like 3D-response surface plot, portraying the maximum value of Rel15min at the intermediate levels of Phospholipid 90G, vitamin E TPGS, and PEG 200. The plot shows a sharp rise in Rel15min values at the intermediate levels of PEG 200 and vitamin E TPGS [59], indicating the highest values of Rel15min. Phospholipid 90G showed a negative effect on the release behavior, which could be attributed to its drug solubilization potential.

Figure 1c represents the 3D diagrammatic depiction of the positive influence of intermediate levels of Phospholipid 90G and vitamin E TPGS on the MDT values. However, on
increasing levels of PEG 200, the values of MDT exhibited a declining trend. This unraveled a remarkable influence of lipids and surfactant on MDT, while the cosolvent had varying influence from negligible to high.

The 3D-response surface plot (Fig. 1d) exhibits a sharp decline with increase in the concentration of Phospholipid 90G and PEG 200, while vitamin E TPGS shows increase in the values of DE at its high level. Minimum value of DE was observed at the intermediate levels of vitamin E TPGS and PEG 200, and low levels of Phospholipid 90G.

Figure 1e shows negligible influence of all the constituents on the values of $T_{\text{emul}}$, thus delineating the absence of interaction effect among them. At all the levels of the studied constituents, no significant change was observed ($p > 0.05$).

Figure 1f shows that at the lower levels of Phospholipid 90G, $\text{Perm}_{45\text{min}}$ values were observed to be maximal, followed by decreasing trend with increased levels of vitamin E TPGS. On the contrary, PEG 200 shows declining effect on $\text{Perm}_{45\text{min}}$ values. A hump-shaped curve in the 3D plot was observed at the intermediate levels of Phospholipid 90G, indicating high values of $\text{Perm}_{45\text{min}}$. This clearly supported the fact that Phospholipid 90G helps in faster permeation of drug across the GI tract into the systemic circulation.

Figure 1g exhibit declining values of zeta potential at increasing concentrations of Phospholipid 90G and PEG 200, while vitamin E TPGS shows increase in the zeta potential values at higher levels, followed by a dip at the highest levels. Higher values of zeta potential, required for maintaining physical stability of the nanoformulations, were observed at low to intermediate levels of all the constituents.

**Characterization of the prepared Mgf SPNMS**

**Globule size ($D_{\text{nm}}$), zeta potential, and self-emulsification time ($T_{\text{emul}}$)**

The value of $D_{\text{nm}}$, ranging between 15 and 60 nm, assures the nanomicellar nature of the developed formulations. Emulgents enable to reduce the interfacial tension and stabilize the globules, thus resulting in the formation of smaller globules [60]. Further, nanometric size range of globules can be ascribed to the ability of the cosolvent to facilitate the efficient emulsification and fluidization of the oil-surfactant
blend [61]. Zeta potential was found to range between −20 and −29 mV, indicating the stability of the developed formulation. It is reported in literature that the negative charge in nanomicelles is due to the presence of free fatty acids on oil droplets [62]. $T_{\text{emul}}$ values were observed to range within 22 to 64 s. Less values of $T_{\text{emul}}$ indicated the tendency of the formulation to emulsify faster in order to produce transparent nanoemulsion [53].

**In vitro drug release studies**

From the dissolution studies, nearly complete drug release (> 90%) was observed for all formulations resulted within 1 h indicating faster Mgf release from SPNMS (Fig. 2a). The inset in the figure is a clear testimony to more than 80% of Mgf release in 15 min. Also, significant improvement (i.e., about fivefolds) in the dissolution rate was observed vis-à-vis free Mgf suspension ($p < 0.001$) (Fig. 2b). MDT was found to vary between 3 and 18 min, while %DE was found to vary between 22 and 34%.

**Permeability studies**

Everted gut sac studies indicated that the values of intestinal permeability varied from 59 to 88% for all the developed SPNMS of Mgf. The results are in consonance with literature reports, where the authors also report the increase in membrane permeability with self nano-emulsifying globules [63–65].

**Search for the optimum formulation and validation of QbD**

Selected CQAs were traded-off to arrive at the optimum formulation and to achieve requisite objectives, i.e., smaller $D_{\text{mm}}$, minimal $T_{\text{emul}}$, highest $\text{Rel}_{15\text{min}}$ and maximum $\text{Perm}_{45\text{min}}$. Therefore, the selection criteria were finalized to search the optimized formulation with $D_{\text{mm}} < 50$ nm, zeta potential $< −30$, $T_{\text{emul}} < 1$ min, $\text{Rel}_{15\text{min}} > 80\%$, DE $> 20\%$, MDT $> 7$ min, and $\text{Perm}_{45\text{min}} > 70\%$. Numerical desirability methodology was adopted for identifying the optimum formulation, where all the CQAs exhibited the value of desirability function close to unity. Figure 2c portrays the optimized SPNMS of Mgf, demarcated in the design space overlay plot. The optimized formulation contained Phospholipid 90G (312 mg), vitamin E TPGS (294 mg), and PEG 200 (393 mg), with the values of CQAs as $D_{\text{mm}}$ of 25 nm, zeta potential of $−25$, $T_{\text{emul}}$ of 39 s, $\text{Rel}_{15\text{min}}$ of 82%, DE of 26%, MDT of 10, and $\text{Perm}_{45\text{min}}$ 73%, respectively. The TEM analysis of the optimized formulation (Fig. 2d) evidently indicated spherical globules of the SPNMS formed with a mean size of about 15 nm.

**Cell line results**

**Cell viability assay**

Various percentage cell viability plots portray that Mgf-SPNMS show the higher toxicity towards MCF-7, suggesting faster onset of action in 24 h, whereas hardly any cell death was observed for MDA-MB-231 cells at the same time-point. Maximum cell death for MDA-MB-231 cells at similar concentration ranges was observed at 72 h. Also, IC$_{50}$ value for MCF-7 cells was found to be 37.56, 22.65, and 4.37 nM at 24, 48, and 72 h, respectively, while negligible cell death was observed at 24 h and a slightly higher IC$_{50}$, i.e., 52.13 and 45.39 nM, was observed with MDA-MB-231 at 48 and 72 h, respectively (Fig. 2e–j). This could be attributed to the higher accumulation of Mgf-SPNMS in MCF-7 than MDA-MB-231 cells, which is known to express P-gp efflux transporters. The higher expression of P-gp receptors on MDA-MB-231 might be responsible for lower accumulation of Mgf-SPNMS in these cells [66]. Moreover, triple negative MDA-MB-231 cells, which bear an aggressive phenotype, usually respond less favorably to the compounds than the less aggressive, estrogen receptor positive, MCF-7 breast cancer cells [67, 68].

**Qualitative and quantitative cellular uptake**

On investigating the cellular uptake on MCF-7 and MDA-MB-231 cells, it was observed that Rh-123-SPNMS started migrating within both the cells in 15 min. Qualitative analysis made through the images were processed through Zen Pro 2012, displaying the fluorescent images of Rh-123-SPNMS uptake at various time-points (Fig. 3a, d). The corresponding overlay histograms (Fig. 3a, d), generated after the data were analyzed using the Flowing software, further corroborated the substantial cellular uptake of Rh-123-SPNMS at the same time points, i.e., 15, 30 min, and 1, 2, and 4 h. Through the qualitative and quantitative observations made, intensity of fluorescence was observed to be much higher for MCF-7 cells than for MDA-MB-231 cells, (Fig. 3c, f), suggesting that the SPNMS encountered less hindrance with the former cell lines. Therefore, one could conclude and correlate the cellular viability and uptake results, in which higher and quicker cellular uptake of the formulation is the indicative of the lower IC$_{50}$ values obtained for both the cell lines. Also, it is reported that the higher cellular uptake of the SPNMS is owing to the presence of surfactants, attributing to the enhancement of the permeability and could change the cell integrity [69, 70].

**P-gp efflux assay**

The P-gp efflux assay revealed that at 4 °C, there was no evidence of active transport, as the MDR and BCRP transporters were inactive, leading to higher accumulation of dyes.
inside the cells, as can be clearly evident from the fluorescence intensity (Fig. 4a). On the other hand, incubation at 37 °C showed active efflux of both dyes (Rh-123 and DiOC2); however, in the presence of vinblastine, which blocks both the MRP2 and BCRP transporters, lead eventually to higher fluorescence intensity without any efflux [71]. Relatively less efflux of Rh-123 and DiOC2 in the presence of SPNMS could be attributed to the excipients like vitamin E TPGS [72] and PEG [73, 74], which act as the P-gp efflux inhibitors, which is in total agreement with the literature reports. In this context, SPNMS would be an adept carrier for delivery of Mgf, which is a P-gp substrate [75], facilitate its accumulation in cancer cells by weakening its P-gp mediated efflux.

**Intestinal permeation study of Mgf**

Figure 4b shows that Rh-123 dye, of its own, does not permeate through the intestine, as it has a tendency to get effluxed by P-gp receptors. However, using optimized Rh-123 SPNMS (Fig. 4c), the fluorescent microvilli of the intestine were observed, indicating the penetration of the prepared formulation, majorly due to the droplets being formed in the nanometric size range. Consequently, the outcome from the CLSM study corroborates improved intestinal permeation with SPNMS, ostensibly owing

---

**Fig. 2** 3D-Response surface plots showing the influence of Phospholipid 90G, Vitamin E TPGS, and PEG 200 on the CQAs, viz. a Globule size (D₉₀), b percent drug release in 15 min (Rel15ₐₚₜ), c mean dissolution time (MDT), d dissolution efficiency (DE), e emulsification time (Tₑₐₘ), f permeability in 45 min (Perm₄₅ₐₚₜ), and g zeta potential

**Fig. 3**  a and d Qualitative analysis indicated the increased cellular uptake with the increase in the Rh-123 intensity for MCF-7 and MDA-MB-231, respectively. b and e Flow cytometry histogram overlays for MCF-7 and MDA-MB-231 cells of Rh-123 SPNMS following control (untreated cells), 15 min, 30 min, 1 h, 2 h, and 4 h incubation at 37 °C. c and f Fluorescence intensity plotted vs. time also corroborated the cellular uptake for MCF-7 and MDA-MB-231, respectively
to the formation of nano-micelles and the presence of vitamin E TPGS [72] and PEG to act as P-gp inhibitors [74].

**In situ intestinal perfusion studies**

These studies explore the absorption and permeation behavior of a drug, when administered as an oral formulation [24]. With SPNMS, enhanced values of absorptivity and permeability parameters of Mgf were observed vis-à-vis pure bioactive. As is evident from Fig. 5a, Mgf SPNMS showed significantly escalation in the values of ($p < 0.001$) absorption number (An) by 8.12-fold and 3.54-fold, vis-à-vis pure Mgf alone, and with verapamil, respectively. The amount of drug transferred across the GI tract, where Mgf SPNMS exhibited distinct superiority over free bioactive, indicated enhanced drug absorption characteristics [76]. Verapamil, being a potent P-gp inhibitor, was able to improve the permeation and absorption parameters, but only up to a limited extent [77, 78]. Further, a significant increase ($p < 0.01$) in the values of fraction drug absorbed (Fa) was also observed for Mgf SPNMS (i.e., 4.06-fold), and Mgf administered with verapamil (i.e., 3.64-fold) vis-à-vis pure Mgf. The aforementioned results indicated notable augmentation in the absorption potential of Mgf SPNMS, ostensibly due to transport of bioactive through lymphatic pathways via circumnavigation of its first-pass effect in the liver [24, 79, 80].

Similarly, in case of permeability parameters, the values of effective permeability ($P_{eff}$) also showed significant, i.e., nearly 6.56-fold and 2.57-fold improvement with SPNMS of Mgf and Mgf-verapamil ($p < 0.001$ each) vis-à-vis pure Mgf, respectively. Likewise, significant increase ($p < 0.001$) in the corresponding values of wall permeability ($P_{wall}$) was also observed by about 6.88-fold and 4.11-fold. The greater values of $P_{eff}$ and $P_{wall}$ delineate increase in the permeability and uptake characteristics of the optimized formulation, plausibly ascribed to improved permeability and decreased efflux due to the incorporation of emulsifying excipient in the formulations [81, 82].

**In vivo pharmacokinetic studies**

Following per oral administration of Mgf SPNMS and pure Mgf, plasma levels were monitored in rat at the designated time-points. Thus, the pharmacokinetic profile (Fig. 5b) shows
considerable difference in the plasma concentrations for MgfSPNMS vis-à-vis pure Mgf (dose equivalent to 30 mg/kg [39]) at all the time-points studied ($p < 0.001$). Furthermore, a linear decline in the post-$T_{\text{max}}$ log concentration-time profile showed that the drug profile follows 2-CBM kinetics [19]. Table 1 shows various calculated pharmacokinetic parameters for Mgf and Mgf SPNMS with statistically significant ($p < 0.001$) difference among all the parameters as estimated in rats treated with pure plant bioactive versus its SPNMS formulation.

Nearly 4.22- and 2.96-fold increase in the magnitude of $C_{\text{max}}$ and AUC was noted on comparing with pure drug ($p < 0.001$), respectively. Moreover, there was 2.65-fold reduction in $T_{\text{max}}$ vis-à-vis pure Mgf ($p < 0.001$), thus corroborating quite faster onset of action owing to improvement in absorption rate. Besides, maximal variation was observed in the values of $K_a$, indicating enhanced oral drug absorption of Mgf SPNMS revealing nearly 3.59-fold increase in $K_a$ over plain Mgf ($p < 0.001$). By and large, the pharmacokinetic

Fig. 4  a  Relatively higher fluorescence intensity index indicates inhibition of MDRI and BCRP transporters maximally by Mgf-SPNMS loaded with Rh-123 and DiOC$_2$ dye, respectively. b Shows no migration of Rh-123 dye into the intestine. c Rh-123 loaded SPNMS has migrated to microvilli of intestine, indicating its better absorption. d Histopathological findings were examined on comparing with the (a) untreated rat after administering saline solution, (b) plain Mgf, (c) blank SPNMS formulation, and (d) Mgf SPNMS. (1) Kidney (a, b, c, d): glomeruli, tubules, and blood vessels are within normal limits. (2) Heart (a, b, c, d): endocardium, epicardium, and myocardium do not show any significant changes. (3) Pancreas (a, b, c, d): pancreatic acini and islets do not show any significant changes. (4) Brain (a, b, c, d): the meninges, cerebral cortex, white matter, cerebellum, hippocampus, and choroid plexus are within normal limits. (5) Lung (a, b, c, d): the pleura, parenchyma, and the interstitium do not show any significant changes. (6) Small intestine (a, b, c, d): ileum shows normal villi and the brush borders are maintained. No other significant changes are observed. (7) Large intestine (a, b, c, d): mucosa, submucosa, muscularis propria, and serosa are within normal limits. (8) Spleen (a, b, c, d): the splenic red and white pulp does not show any significant changes and are within normal limits. (9) Liver (a, b, c, d): the portal tracts, central vein, and sinusoids do not show any significant changes. (10) Stomach (a, b, c, d): mucosa, submucosa, muscularis propria, and serosa do not show any significant changes. Pictures of whole blood extracted from rats after various treatments e control, f Mgf, and g Mgf SPNMS
studies in rats ratified the superiority of the formulated Mgf SPNMS in enhancing oral absorption of Mgf.

**In vivo toxicity studies**

Figure 4d portrays no histopathological change(s) in all the vital organs, indicating that all the three treatments, i.e., Mgf (Fig. 4d (b)), blank (Fig. 4d (c)), and Mgf SPNMS (Fig. 4d (d)) were found to be quite biosafe as that of control (Fig. 4d (a)). Further, all the treated groups, i.e., Mgf, blank SPNMS, and Mgf-loaded SPNMS showed insignificant \((p > 0.05)\) pathological changes vis-a-vis the control group.

The whole blood count analysis revealed that all the three treatments were not significantly \((p > 0.05)\) affecting the white blood cells (WBC), red blood cells (RBC), hemoglobin (HGB), hematocrit (HCT), and platelet (PLT) count. Treatments with Mgf, blank SPNMS, and Mgf SPNMS decreased the values of WBC, RBC, HGB, and PLT, but the change was not found to be that profound (Table 2). The slides of the blood sample were prepared and observed under upright light microscope. Results showed no morphological changes in the shape of RBC, when treated with any of the formulation on comparing with the control (Fig. 4e–g). As it is evident from the histopathology studies (Fig. 4d) that the Mgf alone, blank SPNMS and Mgf SPNMS do not show any sign of toxicity on all the vital organs. The results are in accordance with the literature reports where the blank nanomicelles have shown practically no toxicity \([83, 84]\).

**Conclusions**

In the current studies, SPNMS of Mgf were systematically and successfully developed, which finally composed of Phospholipid 90G, vitamin E TPGS, and PEG 200. Apart from its surfactant like property, vitamin E TPGS was incorporated in the formulation to prevent any possible oxidation of Mgf, and its level was kept as constant throughout the study. In this piece of work, in vitro, in situ, and in vivo studies carried out on the formulations proved these nanostructures to be highly superior to pure bioactive. The toxicity studies confirmed that the ingredients employed in the formulations were quite biosafe. Therefore, it can be concluded that SPNMS with high drug pay-load possess tremendous promise to augment oral bioavailability of Mgf and several other agents of BCS class IV marked with poor solubility and permeability characteristics like Mgf.

**Table 1** Pharmacokinetic parameters obtained from in vivo plasma level studies in rat following oral administration of Mgf and its SPNMS

| Treatment formulations | Pharmacokinetic parameters |
|------------------------|-----------------------------|
|                        | \(C_{\text{max}}\) (ng.h\(^{-1}\)) | \(AUC_{\text{last}}\) (h × ng.ml\(^{-1}\)) | \(\frac{C_{\text{max}}}{AUC}\) (h\(^{-1}\)) | \(K_{a}\) (h\(^{-1}\)) | \(T_{\text{max}}\) (h) | MRT (h) | Cl (mL.h\(^{-1}\)) |
| Mgf                    | 297.14 ± 56.36               | 213.38 ± 25.13               | 0.098                        | 0.32 ± 0.09              | 3.08 ± 0.18           | 8.16 ± 1.73       | 2543.44 ± 453.42  |
| Mgf SPNMS              | 1254.62 ± 182.15             | 8962.15 ± 357.18             | 0.017                        | 1.15 ± 0.25              | 1.43 ± 0.24           | 14.19 ± 1.65      | 1245.72 ± 267.13  |

All the data represented as mean ± SD \((n = 3)\)
Table 2  Whole blood count parameters obtained from blood of rats following various treatments of Mgf and its SPNMS

| Mode       | Control Count | Mgf Count | Blank SPNMS Count | Mgf SPNMS Count |
|------------|---------------|-----------|-------------------|-----------------|
| WBC        | 19.8 × 10^3/μL | 16.4 × 10^3/μL | 18.7 × 10^3/μL | 17.5 × 10^3/μL |
| RBC        | 10.78 × 10^6/μL | 8.21 × 10^6/μL | 9.53 × 10^6/μL | 7.48 × 10^6/μL |
| HGB        | 15.14 g/dL    | 14.54 g/dL | 14.10 g/dL | 13.32 g/dL |
| HCT        | 45.7%         | 43.9%     | 44.9% | 42.6% |
| PLT        | AG* 760 × 10^3/μL | AG* 589 × 10^3/μL | AG* 745 × 10^3/μL | AG* 638 × 10^3/μL |

*All values are mean ± 3

Acknowledgements The financial grants received from the University Grant Commission (UGC), New Delhi, India, to Ms. Rajneet Kaur Khurana under the RFMS scheme-F. No. 5-94/2007(BSR) is deeply acknowledged. The authors also acknowledge the use of the biomedical facilities of the University of Central Lancashire for cell culture experiments. The authors gratefully acknowledge the generosity of M/s Stat-Ease Inc., Minneapolis, USA, for providing one perpetual license and multiple single annual license of the Design Expert® software, version 9.0.

Compliance with ethical standards

The animal experiments were performed in accordance with the recommendations of the committee for the purpose of control and supervision of experiments on animals (CPSCEA), India. The study protocol was approved by the institutional animal ethics committee (IAEC) of Panjab University, Chandigarh (Protocol no. 578/IAEC dated 1/08/2016).

Conflict of interest The authors declare that they have no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Mujawdiya PK, Kapur S. Mangiferin: A potential natural molecule for management of metabolic syndrome. Int J Pharm Pharm Sci. 2015;7:9–13.
2. Takeda T, Tsubaki M, Kino T, Yamagishi M, Iida M, Itoh T, et al. Mangiferin induces apoptosis in multiple myeloma cell lines by suppressing the activation of nuclear factor kappa B-inducing kinase. Chem Biol Interact. 2016;251:26–33.
3. Shoji K, Tsubaki M, Yamazoe Y, Satou T, Itoh T, Kidera Y, et al. Mangiferin induces apoptosis by suppressing Bcl-xL and XIAP expressions and nuclear entry of NF-kappaB in HL-60 cells. Arch Pharm Res. 2011;34(3):469–75.
4. Pan LL, Wang AY, Huang YQ, Luo Y, Ling M. Mangiferin induces apoptosis by regulating Bcl-2 and Bax expression in the CNE2 nasopharyngeal carcinoma cell line. Asian J Cancer Prev. 2014;15(17):7065–8.
5. de Souza JRR, Feitosa JPA, Ricardo NMPS, Trevisan MTS, de Paula HCB, Ulrich CM, et al. Spray-drying encapsulation of mangiferin using natural polymers. Food Hydrocoll. 2013;33(1):10–8.
6. Yoshimi N, Matsunaka K, Katayama M, Yamada Y, Kuno T, Qiao Z, et al. The inhibitory effects of mangiferin, a naturally occurring glucosylxanthone, in bowel carcinogenesis of male F344 rats. Cancer Lett. 2001;163(2):163–70.
7. Rajendran P, Ekambaram G, Magesh V, Saktihsekaran D. Chemopreventive efficacy of mangiferin against benzo(a)pyrene induced lung carcinogenesis in experimental animals. Environ Toxicol Pharmacol. 2008;26(3):278–82.
8. Tsubaki M, Takeda T, Kino T, Itoh T, Imano M, Tanabe G, et al. Mangiferin suppresses CIA by suppressing the expression of TNF-α, IL-6, IL-1β, and RANKL through inhibiting the activation of NF-κB and ERK1/2. Am J Transl Res. 2015;7(8):1371–81.
9. Núñez-Sellés AJ. Antioxidant therapy: myth or reality? J Braz Chem Soc. 2005;16(4):699–710.
10. Roberts HJ. The mythology of antioxidant therapy. Tex Heart Inst J. 2004;31(3):335–6.
11. Chem YQ. Mangiferin. 2016; Available from: http://chemyq.com/En/xz/xz5/45984fmkex.htm.
12. Basheer L, Kerem Z. Interactions between CYP3A4 and dietary polyphenols. Oxidative Med Cell Longev. 2015;2015:854015.
13. Khurana RK, Kaur R, Lohan S, Singh KK, Singh B. Mangiferin: a promising anticancer bioactive. Pharm Pat Anal. 2016;5(3):169–81.
14. FooDB. showing compound mangiferin (FDB012803). 2016.
15. Showing compound mangiferin 6′-gallate (FDB018856) (2016. http://foodb.ca/compounds/FDB018856).
16. Qin L, Yuijiang W, Gang D, Zhiping W, Xiao D, Qin Q, et al. Host-guest inclusion system of mangiferin with β-cyclodextrin and its derivatives. Mater Sci Eng C Mater Biol Appl. 2013;33(4):2386–91.
17. da Rocha Ferreira F, Valentima LB, Luís Catarí Ramones E, Salles Trevisan MT, Olea-Azar C, Perez-Cruz F, et al. Antioxidant activity of the mangiferin inclusion complex with β-cyclodextrin. LWT Food Sci Technol. 2013;51(1):129–34.
18. Yang XZY, Chen Y, Liao X, Gao C, Xiao D, Qin Q, et al. Host-guest inclusion system of mangiferin with β-cyclodextrin and its derivatives. Mater Sci Eng C Mater Biol Appl. 2013;33(4):2386–91.
19. Bhattacharyya S, Ahmmed SM, Saha BP, Mukherjee PK. Soya phospholipid complex of mangiferin enhances its hepatoprotective by improving its bioavailability and pharmacokinetics. J Sci Food Agric. 2013;94(7):1380–8.
20. Khurana RK, Bansal AK, Beg S, Burrow AJ, Katare OP, Singh KK, et al. Enhancing biopharmaceutical attributes of phospholipid complex-loaded nanostructured lipidic carriers of mangiferin: systematic development, characterization and evaluation. Int J Pharm. 2017;518(1–2):289–306.
21. Xiao W, Hou J, Ma J, Yu B, Ren J, Jin W, et al. Mangiferin loaded magnetic PCEC microspheres: preparation, characterization and anti-tumor activity studies in vitro. Arch Pharm Res. 2014;30(13):261–9.

22. Pichot R, Watson RL, Norton IT. Phospholipids at the interface: current trends and challenges. Int Mol Sci. 2013;14(6):11767–94.

23. Singh B, Beg S, Khurana RK, Sandhu PS, Kaur R, Katare OP. Recent advances in self-emulsifying drug delivery systems (SEDDS). Crit Ther Drug Carrier Syst. 2014;31(2):121–85.

24. Singh B, Bandopadhyay S, Kapil R, Singh R, Katare O. Self-emulsifying drug delivery systems (SEDDS): formulation development, characterization, and applications. Crit Rev Ther Drug Carrier Syst. 2009;26(5):427–521.

25. Hou J, Sun E, Zhang Zh, Wang J, Yang L, Cui L, et al. Improved oral absorption and anti-lung cancer activity of paclitaxel-loaded mixed micelles. Drug Deliv. 2017;24(1):261–9.

26. Zhang D, Kong YY, Sun JH, Hsiao SJ, Zhou M, Gui YL, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017;12:2081–108.

27. Akula S, Gurram AK, Devireddi SR. Evaluation of surfactant effect on self micro emulsifying drug delivery system (SMEDDS) of lercanidipine hydrochloride: formulation and evaluation. J Pharm Innov. 2015;10:374–87.

28. Narayana L, Chella N, Kumar D, Shastri NR. Design of a novel IV lipid-based delivery system for improved delivery of drugs with low partition coefficient. J Liposome Res. 2015;25(4):325–33.

29. Pattewar S, Kasture S, Pande V, Sharma S. Self microemulsifying delivery system: a lipid based drug delivery system. Int J Pharm Sci Res. 2014;7(2):443–52.

30. Sarpal K, Pawar YB, Bansal AK. Self-emulsifying drug delivery systems: a strategy to improve oral bioavailability. CRIPS. 2010;11(3):42–9.

31. Gaonkar RH, Ganguly S, Dewanjee S, Sinha S, Gupta A, Chattopadhyay D, et al. Garcinol loaded vitamin E TPGS emulsified PLGA nanoparticles: preparation, physicochemical characterization, in vitro and in vivo studies. Sci Rep. 2017;7(1):530.

32. Zhu H, Chen H, Zeng X, Wang Z, Zhang X, Wu Y, et al. Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance. Biomaterials. 2014;35(7):2391–400.

33. Zhao D, Zhang H, Yang S, He W, Luan Y. Redox-sensitive nPEGS-SS-PTX/TPGS mixed micelles: an efficient drug delivery system for overcoming multidrug resistance. Int J Pharm. 2016;515(1–2):281–92.

34. Singh B, Kapil R, Nandi M, Ahuja N. Developing oral drug delivery systems using formulation by design: vital precepts, retrospective and prospects. Expert Opin Drug Deliv. 2011;8(10):1341–60.

35. Singh B, Kaur A, Dhiman S, Garg B, Khurana RK, Beg S. QBd-enabled development of novel stimuli-responsive gastroretentive systems of acyclovir for improved patient compliance and bio-pharmaceutical performance. AAPS PharmSciTech. 2016;17(2):454–65.

36. Siddhaye AA, Bhran KC, Zambare S, Abubaker M, Nirmalan N, Singh KK. Bio-inspired artemether-loaded human serum albumin nanoparticles for effective control of malaria-infected erythrocytes. Nanomedicine. 2016;11:2809–28.

37. Khurana RK, Rao S, Beg S, Katare OP, Singh B. Systematic development and validation of a thin-layer densitometric bioanalytical method for estimation of mangiferin employing analytical quality by design (AQbD) approach. J Chromatogr Sci. 2016;54(5):829–41.

38. Singh AK, Chaurasiya A, Awasthi A, Mishra G, Asati D, Khar RK, et al. Oral bioavailability enhancement of exemestane from self-microemulsifying drug delivery system (SMEDDS). AAPS PharmSciTech. 2009;10(3):906–16.

39. Bartoszewski R, Hering A, Marszall M, Stefanowicz Hajduk J, Bartoszewiska S, Kapoor N, et al. Mangiferin has an additive effect on the apoptotic properties of hesperidin in Cyclopaia sp. tea extracts. PLoS One. 2014;9(3):e92128.

40. Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. Free Radic Biol Med. 2007;43(1):4–15.

41. Sandhu PS, Kumar R, Katare OP, Singh B. Surface-tailored nanomicelles containing quercetin-salicylic acid physical complex for enhanced cellular and in vivo activities: a quality by design perspective. Nanomedicine (Lond). 2017;12(11):1281–303.

42. Craig DQM, Barker SA, Banning D, Booth SW. An investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int J Pharm. 1995;114:103–10.

43. Beg S, Raza K, Kumar R, Chadha R, Katare OP, Singh B. Improved intestinal lymphatic drug targeting via phospholipid complexed-loaded nanolipospheres of rosuvastatin calcium. RSC Adv. 2016;6:8173–87.

44. Egger AE, Rappel C, Jakupec MA, Hartinger CG, Keppler BK. Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. J Anal At Spectrom. 2009;24(1):51–61.

45. Martins S, Costa-Lima S, Carneiro T, Cordeiro-da-Silva A, Souto EB, Ferreira DC. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int J Pharm. 2012;430(1–2):216–27.

46. Mele L, Zhang Y, Zheng Y, Tian G, Song C, Yang D, et al. A novel docetaxel-loaded poly (ε-caprolactone)/pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatment. Nanoscale Res Lett. 2009;4(12):1530–9.

47. Katayama K, Noguchi K, Sugimoto Y. Regulations of P-glycoprotein/ABC1/MDR1 in human cancer cells. J Nan Sci. 2014;14:476974.

48. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003;22:7340–58.

49. Kapse-Mistry S, Govender T, Srivastava R, Yergeri M. Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol. 2014;5:159.

50. Khurana RK, Beg S, Burrow AJ, Vashishta RK, Katare OP, Kaur S, et al. Enhancing biopharmaceutical performance of an anticancer drug by long chain PUFA based self-nanoemulsifying lipidic nanocellular systems. Eur J Pharm Biopharm. 2017;121:42–60.

51. Holtfreter MC, Stachou O, Reichard M, Loebemann M, Guthoff RF, Reininger EC. Confocal laser scanning microscopy for detection of schistosoma mansoni eggs in the gut of mice. PLoS One. 2011;6(4):e18799.

52. Bandopadhyay S, Katare OP, Singh B. Optimized self nano-emulsifying systems of cetuximab with enhanced bioavailability potential using long chain and medium chain triglycerides. Colloids Surf B Biointerfaces. 2012;100:50–61.

53. Beg S, Jena SS, Patra Ch N, Rizwan M, Swain S, Surti J, et al. Development of solid self-nanoemulsifying granules (SSNEmGs) of ondansetron hydrochloride with enhanced bioavailability potential. Colloids Surf B Biointerfaces. 2013;101:414–23.

54. El-Sayad HI, Ismail MF, Shalaby FM, Abou-El-Magd RF, Gaur EB, Ferreira DC. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int J Pharm. 2012;430(1–2):216–27.

55. Mei L, Zhang Y, Zheng Y, Tian G, Song C, Yang D, et al. A novel docetaxel-loaded poly (ε-caprolactone)/pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatment. Nanoscale Res Lett. 2009;4(12):1530–9.

56. Bandyopadhyay S, Katare OP, Singh B. Self-emulsifying drug delivery systems of cetuximab with enhanced bioavailability potential using long chain and medium chain triglycerides. Colloids Surf B Biointerfaces. 2012;100:50–61.

57. Singh B, Jena SS, Patra Ch N, Rizwan M, Swain S, Surti J, et al. Development of solid self-nanoemulsifying granules (SSNEmGs) of ondansetron hydrochloride with enhanced bioavailability potential. Colloids Surf B Biointerfaces. 2013;101:414–23.

58. El-Sayad HI, Ismail MF, Shalaby FM, Abou-El-Magd RF, Gaur EB, Ferreira DC. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int J Pharm. 2012;430(1–2):216–27.

59. Mei L, Zhang Y, Zheng Y, Tian G, Song C, Yang D, et al. A novel docetaxel-loaded poly (ε-caprolactone)/pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatment. Nanoscale Res Lett. 2009;4(12):1530–9.
64. Jeevana JB, Sreelakshmi K. Design and evaluation of self-nanoemulsifying drug delivery systems, their applications and importance in novel drug delivery. JSIR. 2014;3(2):273–81.
65. Singh B, Pahuja S, Kapil R, Ahuja N. Formulation development of oral controlled release tablets of hydralazine: optimization of drug release and bioadhesive characteristics. Acta Pharma. 2009;59(1):1–13.
66. Uma Suganya KS, Govindarajua K, Ganesh Kumara V, Prabhu D, VelooKuttya R, Feng SS. Cetuximab conjugated vitamin E TPGS for oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58(3):173–82.
67. Ediriweera MK, Tennekoon KH, Samarakoon SR, Thabrew I, Dilip MB-231 & MCF-7). Appl Surf Sci. 2016;317:415
68. Yadav SK, Parvez N, Sharma PK. An insight to self-emulsifying drug delivery systems, their applications and importance in novel drug delivery. JSIR. 2014;3(2):273–81.
69. Effentakis M, Al-Hmoud H, Buckton G, Rajan Z. The influence of stabilizers on drug release from a hydrophobic matrix. Int J Nanomedicine. 1991;70:153–8.
70. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2000;50(1):179–88.
71. Patel J, Kevin G, Patel A, Raval M, Sheth N. Design and development of a self-nanoemulsifying drug delivery system for oral delivery of self-emulsifying drug delivery systems for improved oral absorption of lipophilic drugs. Eur J Pharm Biopharm. 2010;70(2):195–201.
72. Avachat AM, Patel VG. Self nanoemulsifying drug delivery system of stabilized ellagic acid-phospholipid complex with improved dissolution and permeability. Saudi Pharm J. 2015;23(3):276–89.
73. Jeevana JB, Sreelakshmi K. Design and evaluation of self-nanoemulsifying drug delivery system of fluoxetine. J Young Pharm. 2011;3(1):4–8.
74. Kumar A, Jaiswal M. Effect of self nanoemulsifying drug delivery system (SNEDDS) on intestinal permeation and anti-diabetic activity of Berberis aristata extract: in-vitro and ex-vivo studies. J Nanopharm Drug Deliv. 2016;3:51–62.
75. Uma Suganya KS, Govindarajua K, Ganesh Kumara V, Prabhu D, Arulvasu C, Stalin Dhasa T, et al. Anti-proliferative effect of biogeneric gold nanoparticles against breast cancer cell lines (MDA-MB-231 & MCF-7). Appl Surf Sci. 2016;317:415–24.
76. Ediriweera MK, Tennekoon KH, Samarakoone SR, Thabrew I, Dilip De Silva E. A study of the potential anticancer activity of Mangifera zeylanica bark: evaluation of cytotoxic and apoptotic effects of the hexane extract and bioassay-guided fractionation to identify phytochemical constituents. Oncol Lett. 2016;11(2):1335–44.
77. VelooKuttya R, Feng SS. Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. Biomaterials. 2013;34:10160–71.
78. Zhang L, Zhu W, Yang C, Guo H, Yu A, Ji J, et al. A novel folate-modified self-microemulsifying drug delivery system of curcumin for colon targeting. Int J Nanomedicine. 2012;7:151–62.
79. Sobhani H, Tarighi P, Ostad SN, Shafiati A, Nafissi-Varchesh N, Aboofazeli R. Formulation development and toxicity assessment of triacetin mediated nanoemulsions as novel delivery systems for rapamycin. Iran J Pharm Res. 2015;14:3–21.
80. International C. Multidrug resistance direct dye efflux assay; Cat. No. ECM910. USA and Canada 2016.
81. Collinot EM, Baldes C, Schaefer UF, Edgar KJ, Wempe MF, Lehr CM. Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of site and time of access. Mol Pharm. 2010;7(3):642–51.
82. Wang SW, Monagle J, McNulty C, Putnam D, Chen H. Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process. J Pharm Sci 2004;93(11):2755–67.
83. Werle M. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm Res. 2008;25(3):500–11.
84. Louisa M, Soediro TM, Suyatna FD. In vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by mangiferin in doxorubicin-treated MCF-7 cells. Asian Pac J Cancer Prev 2014;15(4):1639–42.
85. Madan J, Chawla G, Arora V, Malik R, Bansal AK. Unbiased membrane permeability parameters for gabapentin using boundary layer approach. AAPS J. 2005;7(1):E224–30.
86. Karwatsky J, Lincoln MC, Georges E. A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity. Biochemistry. 2003;42(42):12163–73.
87. Abdallah HM, Al-Abd AM, El-Dine RS, El-Halawany AM. P-glycoprotein inhibitors of natural origin as potential tumor chemosensitizers; a review. J Adv Res. 2014;6(1):45–62.
88. Porter CJ, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev. 2001;50(1–2):61–80.
89. Abdallah HM, Al-Abd AM, El-Dine RS, Halawany AM. P-glycoprotein inhibitors of natural origin as potential tumor chemosensitizers: a review. J Adv Res. 2014;6(1):45–62.